Drugs / ROSABULIN
ROSABULIN
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00276913 | Jun 2004 → ? | — | Synta Pharmaceuticals Corp. | Completed | No outcome recorded |
| Phase 1 | NCT00088101 | Feb → Dec 2004 | leukemia, lymphoma, metastatic malignant neoplasm | Synta Pharmaceuticals Corp. | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ROSABULIN | ChEMBL registry synonym — accepted as the source's own label CHEMBL271068 ↗ |
| Known as | Rosabulina | ChEMBL registry synonym — accepted as the source's own label CHEMBL271068 ↗ |
| Known as | Rosabuline | ChEMBL registry synonym — accepted as the source's own label CHEMBL271068 ↗ |
| Known as | STA-5312 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00088101 ↗ |
| Modality | Small molecule | — CHEMBL271068 ↗ |
| Route | Intravenous | “STA-5312 administered intravenously” NCT00088101 ↗ |